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1. Introduction 
 
1.1 Coronary Artery Disease 
 
Coronary artery disease and subsequent myocardial infarction are major reasons of 
patient mortality (Kramarow et al., 2013, O'Gara et al., 2013). In 2014 chronic 
ischemic heart disease and acute myocardial infarction were the two leading causes 
of death in Germany according to the German Federal Statistical Office 
(Statistisches-Bundesamt-Deutschland, 2014). 
 
Myocardial ischemia occurs, when blood flow in the coronary vessels is restricted 
and supply of oxygen as well as other nutrients to the myocardial tissue is inhibited. 
A common cause of partial or complete blockage of the coronary arteries is 
atherosclerosis, a multifactorial process, induced by damage to the endothelium. 
Cholesterol rich low-density-lipoprotein (LDL) particles infiltrate the intima layer, 
which causes macrophage cells to accumulate oxidized lipids by endocytosis. 
Subsequently the endothelium thickens (Chen et al., 2016). Cytokines enhance the 
fibrotic remodeling process by stimulating smooth muscle cell proliferation. Over time 
the medial layer of the vessel becomes atrophic and the elastic lamina may rupture 
(Gaze, 2013). Collagen forms a hard fibrous cap over the lesion, referred to as fibro-
lipid plaque. This vascular remodeling with thickening of the intimal layer and the 
formation of fibro-lipid plaques is referred to as coronary artery disease (Badimon et 
al., 2012). As the lesion grows the lumen may be narrowed or detached. Thrombi or 
ruptured plaques may travel downstream and completely occlude arteries (Falk, 
2006). If the blood flow is not re-established, myocardial ischemia occurs, cell death 
pathways are induced and eventually cardiomyocytes demise, a process called 
myocardial infarction (Hausenloy et al., 2013). During myocardial infarction patients 
may present with acute coronary syndrome undergoing strong chest pain and 
vegetative symptoms (Bruyninckx et al., 2008).  
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1.2 Myocardial Infarction 
 
Tissue damage and type of cell death during myocardial infarction depend on the 
area supplied by the occluded vessel and the duration of occlusion (Hamacher-Brady 
et al., 2006, Matsumura et al., 1998). Severe ischemia stops oxygen supply and 
alters mitochondrial metabolism with consequent abrogation of its membrane 
potential. Additionally, adenosine triphosphate (ATP) levels decrease quickly causing 
failure of ATP dependent ion pumps, e.g. the Na+-ATPase (Baines, 2009). Active 
Ca2+ efflux and reuptake into the sarcoplasmic reticulum (SR) are limited resulting in 
uncontrolled electrolyte shifts and Ca2+ overload (Yellon et al., 2007). The 
mitochondrial permeability transition pore (mPTP) is an emerging endpoint and its 
opening induced cell death (Baines, 2009). 
 
When mitochondrial respiration halts, the pH decreases and anaerobic metabolism 
takes over causing production of acidic catabolites. Lower pH-values may have 
severe consequences under physiological conditions. During ischemia however, they 
might even be beneficial as they increase the threshold of mPTP opening (figure 1) 
(Griffiths et al., 1995). When reperfusion is restored the pH increases very quickly, 
which might be detrimental to surrounding tissue (Cohen et al., 2007). Furthermore 
these processes are accompanied by activation of intracellular proteases, e.g. 
calpain, which lead to damage of myofibrils and trigger destructive rigor contracture. 
As a consequence of cellular stress the mPTP opens and cell death becomes 
imminent (Padilla et al., 2003).  
 
1.3 Reperfusion Injury 
 
The detrimental effects of arterial occlusion are evident. In contrast, it has been 
discussed controversially, whether the phenomenon of reperfusion injury is a distinct 
process or just an enhancement of damage sustained during ischemia (Kloner, 1993, 
Jennings et al., 1960). In recent years, it has become widely accepted that significant 
damage occurs immediately after reperfusion is restored (Hausenloy et al., 2004b). 
Reperfusion injury can occur in different manners and patients may present 
arrhythmias and stunning while blood flow is re-established (Piper et al., 1998).  
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The current gold standard therapy, to alleviate the extent of damage from coronary 
artery occlusion, is the induction of reperfusion and re-oxygenation through 
pharmacological dissolution or dislodgement of the clot. Thus, making reperfusion 
injury an inevitable side effect (Yellon et al., 2007, Ovize et al., 2010).  
 
As underlying mechanisms, Ca2+ alterations and mPTP opening gained focus as 
closely related key mediators of reperfusion induced-cell death (figure 1) (Ibáñez et 
al., 2015, Piper et al., 1998). During the reperfusion phase, intracellular Na+ may also 
increase, as pH restoration is associated with Na+ influx and impaired Na+ pump 
function (Ruiz-Meana et al., 1999). Na+ influx prompts additional intracellular Ca2+ 
increase through the Na+/Ca2+-exchanger (Marber et al., 1993). When ATP synthesis 
is restored, Ca2+ is pumped into the SR, which may result in fluctuations of Ca2+. 
Ca2+ is released through the ryanodine receptor 2 channel (RyR2), if the cellular 
capacity is exceeded. These quick alterations in Ca2+ concentrations may lead to 
damaging hypercontracture, arrhythmias and mitochondrial Ca2+ overload (figure 1) 
(Ruiz-Meana et al., 2009). 
 
Opening of the mPTP is an emerging point of several involved pathways and leads to 
subsequent cell death during ischemia and reperfusion. The mPTP is a non-specific 
channel located in the mitochondrial membrane (Heusch et al., 2010). Under 
physiological conditions, the mPTP remains mostly closed. Its opening occurs in 
response to the increased concentrations of Ca2+ and is catalyzed by an elevated pH 
during reperfusion. Other processes involved in mPTP opening are high 
concentrations of reactive oxygen species (ROS), inorganic phosphate and reduction 
of the inner membrane potential (Heusch et al., 2010). Consequent cell death is 
triggered by depolarization of the inner mitochondrial membrane potential as well as 
matrix swelling and eventually destruction of the membranes. Thus, the 
intermembrane space is liberated and proteins, such as cytochrome C, activate 
caspases and ultimately induce cell death (Kroemer et al., 2000, Kroemer et al., 
2007). 
 
Taken together, cardiac ischemia/reperfusion injury (I/R) is a major challenge in 
modern medicine. Not only ischemia is detrimental to the myocardium, but also 
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reperfusion injury can constitute to 50% of the final infarct size making its treatment a 
promising approach to reduce cardiac damage (Herzog et al., 1997). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.4 The Concept of Ischemic Conditioning 
 
In 1986 Murry et al. showed that brief cycles of non-lethal ischemia and reperfusion 
prior to prolonged myocardial infarction reduce the final infarct size (Murry et al., 
1986). This concept, known as ischemic preconditioning (IPC, figure 2 A), has been 
successfully replicated in many studies making IPC a promising cardioprotective 
approach (Heusch, 2013). However, as ischemic events are hard to predict in non-
experimental settings, it remains difficult to establish IPC in clinical practice. Hori et 
al. altered the strategy of IPC in 1991 and successfully used gradual restoration of 
blood flow in a dog model to reduce infarct damage (Hori et al., 1991). 
Cardioprotective effects similar to those of IPC were first reproduced by Zhao et al. 
using short repetitive cycles of IPoc (Zhao et al., 2003). Different studies confirmed 
these results (Kin et al., 2004, Yang et al., 2004). This new concept with additional 
figure 1 ▲ Potential Effects of Ischemia and Reperfusion. RISK pathway (blue). Based on 
(Murphy et al., 2008) 
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cycles of I/R after myocardial infarction, referred to as ischemic postconditioning 
(IPoc, figure 2 B), was developed to prevent reperfusion induced damage even after 
the ischemic event (Hausenloy et al., 2016).  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IPoc has been shown to protect against numerous aspects of I/R, including reduction 
of infarct size, interstitial and intracellular edema. It decreases Ca2+-accumulation, 
ROS generation as well as the inflammatory response (Hausenloy et al., 2016).  
 
As underlying mechanisms of cardioprotection Tsang et al. described involvement of 
the pro-survival reperfusion injury salvage kinase pathway (RISK, figure 1 and 
section 1.7) (Tsang et al., 2004). Later, the survivor activating factor enhancement 
pathway (SAFE) was identified to mediate cardioprotective effects of IPoc as well 
(section 1.7) (Hausenloy et al., 2011).  
 
figure 2 ▲ Concept of Pre- and Postconditioning. Short intermittent, non-lethal cycles of 
cardioprotective stimuli (ischemia, anesthetics, pharmacological agents), preconditioning (A), prior 
to prolonged ischemia may reduce myocardial infarct size. Short periods of intervention after 
prolonged ischemia, postconditioning (B), may induce similar cardioprotection. Some stimuli may 
only be cardioprotective, when applied for a single cycle after prolonged ischemia, also referred to 
as postconditioning (C). 
 
B 
A 
C 
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1.5 Pharmacological Conditioning 
 
Cardioprotection may also be induced through certain pharmacological agents 
mimicking the effects of IPC and IPoc, referred to as pharmacological conditioning. 
Several substances have been investigated for their cardioprotective properties 
(Hausenloy et al., 2016). Applying these agents with an alike protocol as IPC and 
IPoc, with short application cycles before (pharmacological preconditioning) or after 
(pharmacological postconditioning) prolonged ischemia, results in reduced infarct 
size (Hausenloy et al., 2016). Some substances produce cardioprotection only when 
applied for a single cycle after prolonged ischemia (figure 2 C) (Sonne et al., 2008, 
Hausenloy et al., 2016).  
 
Volatile anesthetics, e.g. sevoflurane (Toller et al., 1999) or isoflurane (Cason et al., 
1997), are recognized to reduce infarct size after myocardial infarction in vitro and in 
vivo similar to ischemic conditioning (IC) (Mullenheim et al., 2002). However, these 
anesthetic gases may have unfavorable side effects on hemodynamics and 
cardiovascular parameters aside from causing anesthesia (Cason et al., 1997). The 
noble gas xenon gained focus as it has been shown to induce cardioprotection in the 
setting of pre- or postconditioning, while causing minimal cardiovascular changes 
(Preckel et al., 2000, Preckel et al., 2002, Weber et al., 2006).  
 
Interestingly, the pathways underlying the cardioprotective effects in anesthetic 
conditioning are very similar to the ones induced in IC. Both, RISK and SAFE 
pathway, are known to be mediators involved in cardioprotection with the mPTP as 
an emerging end-point (section 1.7) (Hausenloy et al., 2016, Davidson et al., 2006). 
 
A common challenge for all pharmacological conditioning strategies is their clinical 
translation, which remains difficult, as cardioprotective effects are often reduced or 
abolished in the existence of pathological conditions, e.g. diabetes, hypertension 
and/or several medications like P2Y12-inhibitors (Boengler et al., 2009, Ferdinandy 
et al., 2014). 
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1.6 Helium Conditioning 
 
The noble gas helium is an odorless, colorless, inert, non-anesthetic gas. Helium is 
the sixth most occurring gas in the world and has a density that is approximately six 
times lower than atmospheric air (Oliver, 1984). The physical properties of helium 
reduce airway resistance and turbulences resulting in increased respiratory flow 
(Papamoschou, 1995). The first medical use of helium for respiratory diseases was 
described in 1936 by Barach et al. (Barach et al., 1936). Helium is mostly applied as 
a mixture of helium and oxygen, called heliox and is well established for medical use 
in pulmonary disease like asthma bronchial or chronic obstructive pulmonary disease 
(Valli et al., 2007). Studies investigating helium safety have shown no carcinogenic or 
toxic side effects (Harris et al., 2008). In fact, helium has been used in deep sea 
diving for decades and is used even in children with pulmonary diseases (Hess et al., 
2006, Liet et al., 2015). Taken together, these characteristics make helium potentially 
an ideal medical agent. 
 
In 2007 Pagel et al. first described cardioprotective effects of helium and several 
studies have replicated cardioprotective effects of helium preconditioning with short 
cycles of helium prior to prolonged ischemia (Huhn et al., 2012, Huhn et al., 2009a, 
Pagel et al., 2008a, Pagel et al., 2007). Helium postconditioning (HePoc), with helium 
ventilation during reperfusion, has also been shown to protect from myocardial I/R in 
different experimental studies (Huhn et al., 2009b, Oei et al., 2012). The underlying 
mechanisms of helium conditioning still need further research. However, it has been 
shown that helium preconditioning influences the RISK pathway kinases extracellular 
signal-regulated kinase 1/2 (Erk1/2), phosphatidylinositol 3-kinase (PI3K), protein 
kinase B (Akt) and glycogen synthase kinase-3β (GSK-3β) (Halestrap et al., 2007, 
Nishihara et al., 2007). Thus, it is anticipated that the mentioned molecules might 
play an important role in HePoc. Other involved signaling may include pro-survival 
autophagy as expression of autophagy related genes, beclin-1 (Bcl-1) and 
sequestosome-1, is upregulated during HePoc (Oei et al., 2015b). 
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1.7 Mechanisms Behind Cardioprotection: RISK and SAFE Pathways 
 
At the time of discovery of the concept of IC, the pathways were unknown. First 
studies investigating cardioprotective effects of IC suggested washout of ischemic 
catabolites as well as restauration of ATP synthesis as important underlying effectors 
(Murry et al., 1986). 30 years later the understanding of signaling pathways behind IC 
induced cardioprotection has advanced, indicating a network of complex and diverse 
mechanisms to be responsible for cardioprotection. 
 
One key target of ischemic and pharmacologic conditioning is the RISK pathway 
(Yellon et al., 1999, Hausenloy et al., 2004b). The RISK pathway is a pro-survival 
pathway consisting of several effector-kinases including PI3K, Akt, Erk1/2 and 
proteinkinase Cε (PKCε). Interestingly, these kinases are not arranged into separated 
pathways, but have to be understood as a communicating network of co-factors 
(figure 1) (Hausenloy et al., 2004a). Signaling through PI3K induces cardioprotection 
in I/R through its downstream effector serine-threonine kinase Akt (Tsang et al., 
2004). Like Akt, the activation of Erk1/2 triggers a signal cascade that regulates cell 
proliferation and cell death (Yue et al., 2000). Erk1/2 has been shown to mediate 
different cell pathways (Dagda et al., 2008, Kassan et al., 2016). However, the exact 
mechanisms through which different conditioning strategies activate the RISK 
pathway kinases, are yet unclear. Explanations involve intermediary factors, e.g. 
adenosine or PKC. It is not known, whether these kinases emerge in a mutual 
pathway or use different end-effectors to mediate their pro-survival signals. However, 
several components of the RISK pathway converge on the mitochondria and a role 
for prevention of mPTP opening seems likely (figure 1) (Davidson et al., 2006). 
 
The SAFE pathway is a simultaneously activated signal cascade, which has been 
closely related to the RISK pathway and cardioprotection (Goodman et al., 2008, 
Lecour, 2009). Lecour et al. first described the cardioprotective SAFE pathway, which 
involves the tumor necrosis factor α (TNFα), which in other settings may be 
detrimental (Lecour, 2009). Its activation occurs at the onset of reperfusion, but has 
also been reported for IC (Hausenloy et al., 2016). The SAFE pathway may produce 
cardioprotection independently from the RISK pathway through activation of the 
Janus kinase (JAK) and the signal transducer and activator of transcription 3 
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(STAT3) (Lecour et al., 2005). However, several interactions between RISK and 
SAFE pathway have been described (Somers et al., 2012).  
 
As described previously, mPTP opening is a common consequence of ischemia 
(Weiss et al., 2003). Opening of the mPTP within the first min of reperfusion is 
caused by Ca2+ overload in the mitochondria, oxidative stress and ATP depletion. 
RISK and SAFE pathway activation through IC targets the mitochondria with mPTP 
acting as a converging point to attenuate cellular damage (Hausenloy et al., 2005, 
Hausenloy et al., 2006).  
 
1.8 The Role of Caveolins in Cardioprotection 
 
Caveolae are flask like invaginations of the plasma membrane, which have been 
described first in 1953 by George Palade using electron microscopy (Palade, 1953). 
Since then caveolae have been discovered in most cell types (Patel et al., 2008) with 
only few exceptions, e.g. erythrocytes, lymphocytes and neurons (Yousuke T. 
Horikawa, 2014). Caveolae are lipid enriched structures made of sphingolipids, 
cholesterol and fatty acids (Pike, 2006). They are key mediators of physiological 
cellular functions, including adrenergic receptor regulation, Ca2+-homeostasis, 
endocytosis and surface signaling (Schilling et al., 2015). Interestingly, several of 
these mechanisms have also been shown to be involved in cellular responses to I/R 
and cardioprotection induced by IC (Yousuke T. Horikawa, 2014). 
 
Caveolin (Cav) is the essential structural protein for the formation of caveolae (figure 
3). Caveolins exist in three isoforms, Cav-1, Cav-2 and Cav-3. Cav-1 and Cav-2 are 
expressed by different cell types, including endothelial cells, fibroblasts and 
pneumocytes (Yousuke T. Horikawa, 2014). Cav-3 has been shown to be the 
predominant isoform muscle tissue (Song et al., 1996). Knockout (KO) models have 
been developed for each of the Cav-isoforms with different effects on the organisms 
and support the idea of tissue specificity. While Cav-1 KO mice show absolute 
deprivation of caveolar invaginations in several cell types (Drab et al., 2001, Razani 
et al., 2001), Cav-3 KO mice present with caveolae loss in skeletal as well as 
myocardial muscle cells (Hagiwara et al., 2000). In Cav-2 KO mice no changes of 
caveolae formation in the myocardium were reported, but lung parenchyma showed 
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pathological alterations (Razani et al., 2002). Many functions and signaling 
processes of caveolins are mediated through a scaffolding domain (CSD, figure 3) 
(Sargiacomo et al., 1995, Feron et al., 2006).  
 
The CSD is a 20 amino acid long, hydrophobic region in the cytoplasmic amino 
terminal tail, which can communicate with signaling partners through hydrophobic 
interactions. Several proteins and pathways have been connected to the CSD and 
have been shown to interact with GPCRs (Head et al., 2005), eNOS, Erk1/2, or the 
PI3K/Akt signaling pathway (figure 3) (Ballard-Croft et al., 2006, Fecchi et al., 2006). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cav-1 and Cav-3 activation and signaling may be mediated by I/R (Ballard-Croft et 
al., 2006). Interestingly the infusion of the CSD of Cav-1 into hearts undergoing I/R 
resulted in improved endothelial function and cardiac function (Young et al., 2001). 
Additionally roles of Cav-1 and Cav-3 in cardioprotection have been shown through 
overexpression models of Cav-1 and Cav-3, which present innate resistance to 
figure 3 ▲ Caveolae and Caveolins. Caveolae are small lipid and cholesterol enriched 
invaginations of the plasma membrane. Essential for caveolae formation are caveolins (blue), 
which exist in three isoforms Cav-1, Cav-2, Cav-3. Functioning caveolins form dimers and contain a 
scaffolding domain, CSD (red), which interacts with several signaling proteins (orange box). Based 
on (Ushio-Fukai et al., 2006) 
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cardiac I/R (Schilling et al., 2015). Cav KO models however, prevent conditioning 
induced cardioprotection (Yousuke T. Horikawa, 2014). 
 
As other conditioning strategies, e.g. IC, have been related to caveolins and CSD-
mediated signaling, a role of caveolins in HePoc induced cardioprotection can be 
suspected (Schilling et al., 2015). 
 
1.9 Autophagy in Helium Postconditioning  
 
During myocardial infarction, different survival- and death-pathways influence the 
level and extent of tissue damage as well as clinical outcome. Autophagy, also 
referred to as type II cell death, is a highly regulated process of degradation and 
phagocytosis of cellular components (Thapalia et al., 2014). Autophagic signaling is 
induced by a class-III-PI3K complex involving Vps34 and Bcl-1. A phagophore is 
formed from membrane parts of the mitochondria, ER and/or Golgi apparatus as well 
as endosomes. The phagophore matures forming the autophagosome, which fuses 
with lysosomes sequestering lysosomal acids for target degradation building and 
autolysosome (figure 4) (Glick et al., 2010).  
 
Therefore, autophagy can promote cell survival during cellular stress as digestion of 
cellular structures can provide energy from amino or fatty acids. It may target specific 
cell structures or proteins for digestion (Fink et al., 2005). However, the process can 
also be non-selective and dismantle essential cell components enhancing cellular 
damage (Glick et al., 2010). Consequently the over-activation of autophagy may 
result in cell death or lead to e.g. neurodegenerative, liver or cardiac disorders 
(Konstantinidis et al., 2012).  
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In long living cells, like cardiomyocytes, autophagy of mitochondria, mitophagy, is a 
continuous process helping to maintain cellular functioning (Gottlieb et al., 2009). 
Damaged mitochondria release cytochrome C, which triggers apoptosis, and have a 
significant role in ROS production. Therefore their removal may decrease oxidative 
damage and benefit cellular functioning (Kavazis et al., 2008). Additionally, the 
surviving highly functional mitochondria have a more efficient ATP synthesis and 
higher threshold for mPTP opening. During myocardial infarction, the most damaged 
mitochondria are selectively digested by mitophagy, referred to as mitochondrial 
quality control (Twig et al., 2008). Mitochondrial quality control during cellular stress 
may stimulate mitochondrial biogenesis and increase number of functioning 
mitochondria (Kavazis et al., 2008). Taken together, it can be assumed that 
autophagy and, especially, mitophagy are essential for cardioprotection (Huang et 
al., 2010) and several pharmacological conditioning protocols, including HePoc, 
present upregulated autophagy genes like Bcl-1 (Oei et al., 2015b, Wei et al., 2013).  
figure 4 ▲ Autolysosome Formation. Ubiquitinated Bcl-1 in the Class-III-PI3K complex initiates 
the assembly of a membrane-particles, which elongate and form the phagophore. Sequestosome-1 
mediates LC3-I, which may be conjugated to LC3-II and is involved in recruitment of 
autophagosomal membranes. Sequestosome-1 regulates selective autophagy and identifies 
targets. Fusion with lysosomes results in autolysosome formation and induces degradation of the 
sequestered molecules. Based on (Sriram et al., 2011) 
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1.10 Aims of the Study 
 
HePoc is a safe treatment for myocardial I/R, which reduces infarct size and cardiac 
damage. Further insight on underlying mechanism is needed for clinical 
implementation. In this study, a HePoc rat model, which is, to some extent, resistant 
to cardiac I/R, was employed. Using western blot and quantitative reverse 
transcriptase polymerase chain reaction (qRT-PCR), myocardial caveolins as well as 
RISK pathway kinases and autophagy associated proteins were investigated as 
possible mediators of HePoc induced cardioprotection.  
 
The main goals of the study were: 
 
(I)  To investigate changes of Cav-1 and Cav-3 protein expressions in different 
cellular fractions and blood (through serum analyses) after I/R as well as 
HePoc 
(II)  To evaluate different effects of HePoc on mRNA and protein expression on 
ischemic AAR and non-ischemic NAAR tissue  
(III) To analyze whether activation of RISK pathway and autophagy related 
proteins is associated with HePoc 
 
The results of the present work give new insight in the effects and underlying 
protective signaling of HePoc. Our findings may enable further advancement of 
HePoc research and aid the transfer of HePoc into the clinical setting.  
Materials and Methods 
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2. Materials and Methods 
 
2.1 Materials 
 
2.1.1 Chemicals and Reagents 
 
Chemicals and solutions were purchased from Merck (Amsterdam, the Netherlands), 
Carl Roth (Karlsruhe, Germany), Roche (Almere, the Netherlands) or Sigma-Aldrich 
(Zwijndrecht, the Netherlands), unless stated otherwise. 
 
2.1.2 Antibodies 
 
Antibody Dilution Species Manufacturer 
Actin 1:5000 rabbit Cell Signaling Technology, 
Cambridge, UK 
Cav-1  1:40000 mouse BD Biosciences, Franklin 
Lakes, NJ, USA 
Cav-3  1:20000 mouse BD Biosciences 
Bcl-1   1:1000 rabbit Cell Signaling Technology 
Sequestosome-1 1:2000 mouse Abcam, Cambridge, UK 
PHB1  1:5000 rabbit Cell Signaling Technology 
NaK-ATPase 1:10000 rabbit Cell Signaling Technology 
pAkt  1:500  rabbit Cell Signaling Technology 
Akt 1:2000 rabbit Cell Signaling Technology 
pErk1/2 1:2000 rabbit Cell Signaling Technology 
Erk1/2  1:2000 rabbit Cell Signaling Technology 
pPKCε 1:1000 rabbit Milipore, Billerica, MA, USA 
PKCε  1:2000 rabbit Milipore 
pPI3K  1:2000 rabbit Cell Signaling Technology 
PI3K 1:2000 rabbit Cell Signaling Technology 
 
 
 
Table 1 ▲ List of Antibodies. 
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Table 2 ▲Overview of Primers. 
2.1.3 Oligonucleotides 
 
Gene Direction Sequence 
Cav-1  forward  5’ CGT AGA CTC CGA GGG ACA TC 3’ 
 
 reverse  5’ CGT ACA CTT GCT TCT CAT TCA C 3’ 
Cav-3  forward  5’ CCA AGA ACA TCA ATG AGG ACA TTG TG 3’ 
 
 reverse  5’ GTG GCA GAA GGA GAT ACA G 3’ 
GAPDH  forward  5’ TGC CCC CAT GTT TGT GAT G 3’ 
 
 reverse  5’ GCT GAC AAT CTT GAG GGA GTT GT 3’ 
 
2.1.4 Solutions 
 
Greenberger Lysis Buffer: 8.77 g of sodium chloride together with 1.82 g tris 
(hydroxymethyl) aminomethane (Sigma 7-9®), 0.20 g of magnesium chloride, 
monohydrate, 0.11 g of calcium chloride and 5 ml 1% Triton were diluted in 400 ml 
Milli-Q water. The pH was adjusted to 7.4 with hydrochloric acid and afterwards the 
volume was filled up to 1 l total with Milli-Q water. 100 μl (100 mg/ml) of each 
protease inhibitor, Pepstatin A, Leupeptin and Aprotinine, were added shortly before 
use. 
 
Lysis Stock Solution: 60.57 mg of Sigma 7-9®, 210.00 mg of sodium fluoride, 
36.78 mg sodium orthovanadate and 76.08 mg triethylene glycol diamine tetraacetic 
acid were diluted in 100 ml Milli-Q water. 
 
Tris-hydrochloride, 0.5 mol/l, pH 7.4: 15.8 g of tris-hydrochloride were dissolved in 
150 ml Milli-Q water. The pH was corrected to 7.4 with sodium hydroxide. Milli-Q 
water was added to a total volume of 200 ml. 
 
Inase Inhibitor Mix: Aprotinine 1 mg, Leupeptin 1 mg and Pepstatin A 1 mg were 
mixed with 10 ml tris-hydrochloride solution (0.5 mol/l, pH 7.4). 
Materials and Methods 
16 
Okadaic Acid, 100 μmol/l: 50 μg of okadaic acid potassium salt (stored at -20°C) 
was diluted in 593 μl Milli-Q water. An end concentration of 100 μmol/l was obtained. 
 
Lysis Buffer: 10 ml lysis stock solution was mixed with 200 μl Inase Inhibitor Mix, 
7.7 mg dithiothreitol (DTT) and 100 μl okadaic acid (100 μmol/l). 
 
5x Sample Buffer: 5x Sample Buffer contains 1.0 g sodium dodecyl sulfate (SDS), 
25 mg bromophenol blue and 150 mg Sigma 7-9® in 4 ml Milli-Q water. Then 5 ml 
glycerol were added to the solution, which was next heated to 50°C. The pH was 
adjusted to 6.8 with hydrochloric acid before 1 ml mercaptoethanol was added. 
 
10x 3-Morpholinopropanesulfonic Acid (MOPS) Running Buffer: 60.6 g Sigma7-
9®, 104.6 g MOPS, 10 g SDS, 3 g ethylenediaminetetraacetic acid (EDTA) were 
dissolved in 1000 ml Milli-Q water. 
 
1x MOPS Running Buffer: 50 ml 10x MOPS Running Buffer were added to 450 ml 
Milli-Q water. 
 
10x Transfer Buffer: 30 g Sigma 7-9® and 144 g glycine were dissolved in Milli-Q 
water to a total volume of 1000 ml. 
 
1x Transfer Buffer: 200 ml 10x Transfer Buffer were added to 1400 ml Milli-Q water. 
400 ml methanol were added before the solution was stored at 4°C.  
 
Tween PBS (TBS-T), pH 8: 6 g Sigma 7-9®, 22.2 g sodium chloride and 2 ml Tween 
20® were dissolved in 2000 ml Milli-Q water. Before use, the pH was corrected to 8.0 
with hydrochloric acid. The solution was stored at 4°C. 
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figure 5 ▲ Scheme of Coronary Artery 
Occlusion. LCA = left coronary artery, 
LAD = left anterior descending artery, 
RCA = right coronary artery, AAR = 
(ischemic) area at risk. 
 
2.2 Methods 
 
2.2.1 Ethics 
 
Animal experiments were performed in accordance with the Guide for Care and Use 
of Laboratory Animals (NIH Publication No. 85-23, revised 1996) and approved by 
the Academic Medical Center’s animal ethics committee (DAA102650). 
 
2.2.2 Animal Model of Ischemia/Reperfusion 
 
Male Wistar rats (354 to 426 g, age range of 12 to 16 weeks) were acclimatized for 
seven d with sequences of 12 h light and 12 h dark and access to food and water ad 
libitum. Animals were anesthetized by intraperitoneal S-ketamine (150 
mg/kg)/diazepam (1.5 mg/kg) injection and surgical procedures were performed as 
described previously (Oei et al., 2012). All rats were ventilated mechanically and the 
carotid artery was canulated to register the mean arterial pressure (section 7.3) and 
draw blood samples. Animals were left 
untreated for 15 min before the start of the 
respective experimental protocol. The aortic 
pressure was measured using a fluid filled 
pressure catheter. The analog signal was 
digitalized with an analogue-to-digital 
converter (Powerlab/8SP, ADInstruments Pty 
Ltd, Castle Hill, Australia) and recorded with 
Chart 5.0 for Windows (ADInstruments Pty 
Ltd, Castle Hill, Australia). 
 
The left anterior descending coronary artery 
(LAD) branching out of the left coronary artery 
(LCA) was encircled with a single puncture 5-
0 Prolene suture (Ethicon Johnson&Johnson, Amersfoort, the Netherlands) through 
the myocardium. Regional ischemia was induced by tightening of the suture, which 
was re-opened in order to begin reperfusion (figure 5). In animals subjected to I/R 
only, the ischemic period was followed by 5, 15 or 30 min of reperfusion, respectively 
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figure 6 ▲ Experimental Setting. After 15 min of baseline-stabilization the LAD was ligated to 
commence ischemia in the left ventricle (figure 5). The study groups underwent 15 min of reperfusion 
and 15 min of reperfusion with helium ventilation. The Sham operated group did not undergo ischemia. 
The experiments were performed with 5 and 30 min periods, respectively. However, these results are 
only shown in the appendix as groups showed no significant differences (section 7.1 and 7.2). The 
results and discussion section will focus on the 15 min intervention groups only. (Flick et al., 2016) 
 
(I/R5, 15, 30) (figure 6). The treatment groups were ventilated with heliox (70% 
helium and 30% oxygen, Linde Gas Benelux, Dieren, the Netherlands) at 24 min of 
ischemia ensuring sufficient helium concentrations in the lungs at the onset of 
reperfusion. HePoc was performed for 5, 15 or 30 min of reperfusion (I/R+He5, 15, 
30) (figure 6). The Sham group received surgical treatment without undergoing I/R or 
HePoc. Tissue was obtained from the ischemic area at risk (AAR) and the non-
ischemic, not area at risk (NAAR). AAR and NAAR were separated and ground in a 
pre-cooled mortar (Oei et al., 2015b). The AAR was determined histologically on the 
basis of the pathological demarcation zone at low power view (10x magnification), 
extending from the suture to the apex of the heart (figure 5) (Oei et al., 2015b). AAR 
as well as the NAAR tissue was snap frozen in liquid nitrogen and stored at -80°C 
until further processing.  
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2.2.3 Preparation of Cytosolic-, Membrane- and Mitochondrial- Fractions                               
…...     from Ischemic AAR and Non-Ischemic NAAR Tissue 
 
For fraction separation, lysis buffer, inase-inhibitor mix, DTT and okadaic acid, 
according to section 2.1.4, were added. The samples were mixed with a 
homogenizer (Ultra-Turrax T8, IKA) and 50 µl of the respective sample were pipetted 
into new vials containing 450 μl of Tripur for RNA analyses. The remaining 
homogenate was centrifuged at 1000 g, 4°C for 10 min, the supernatant 
subsequently at 10000 g, 4°C for 15 min. The resulting supernatant was pipetted into 
new vials, while the remaining pellet was re-suspended with lysis buffer (1%Triton X-
100) to be used as the mitochondrial fraction. Samples were centrifuged again at 
5000 g, 4°C for 15 min and the supernatant was used as the cytosolic fraction. The 
pellet was mixed with lysis buffer, vortexed and after 60 min of incubation on ice 
centrifuged at 5000 g, 4°C for 15 min. The supernatant was obtained as the 
membrane fraction (figure 7). All fractions were stored at -80°C.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
figure 7 ◄ Schematic 
Overview of Tissue 
Processing. After 
separation of AAR and 
NAAR the tissue 
homogenate (beige) 
was processed to 
isolate the 
mitochondrial fraction 
(green), the cytosolic 
fraction (blue) and the 
membrane fraction 
(grey). Homogenate-
Tripur-mix was stored 
for further mRNA 
analyses (red). 
RNA Isolation 
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2.2.4 Bradford Protein Assay 
 
Bradford Protein Assays (Bio-Rad, Hercules, CA, USA) were performed in duplicates 
on standard 96-well plates. For the bovine serum albumin (BSA) standard curve 10 µl 
of each pre-diluted BSA standard solutions was pipetted in duplicate. 10 µl of sample 
was pipetted into each well. Afterwards 140 µl/well of Bradford reagent were added 
and mixed on a microplate mixer. Concentrations of each sample were calculated by 
reading the absorbance at 595 nm with a microplate reader. 
 
2.2.5 Western Blot 
 
Protein concentrations were measured as described in section 2.2.4 and diluted to 
align concentrations. Equal amounts of protein were mixed with SDS-PAGE sample 
buffer (SDS, Bromophenol Blue, TrisBase, Glycerol and Mercaptoethanol), the 
samples were vortexed and heated to 95°C for 5 min. Samples were separated by 
SDS-PAGE using Criterion™ XT precast gels (Bio-Rad, Hercules, CA, USA) and 
transferred onto a Immobilin-FL Membrane (Millipore, Billerica, MA, USA). The 
membrane was washed in Odyssey® Blocking Buffer (LI-COR, Lincoln, NE, USA) for 
60 min and incubated with target antibodies overnight (table 1). After washing the 
membrane for 3x5 min in cold, fresh TBS-T, the blot was incubated for 60 min with 
IRDye800 CW or IRDye680 CW conjugated mouse- or rabbit-antibody (1:5000, LI-
COR, Lincoln, NE, USA). The membranes were washed again for 3x5 min and 
scanned using Odyssey ® Infrared Scanning Software v2.1 (LI-COR, Lincoln, NE, 
USA), which was later used for quantification of the blots. Results were presented as 
ratio of the target protein over a fraction-specific reference protein: cytosolic fraction, 
actin; membrane fraction, tubulin; mitochondrial fraction prohibitin-1 (PHB1) (for Cav-
1, Cav-3 and RISK pathway proteins) or NaK-ATPase (for Bcl-1 and sequestosome-
1). RISK pathway proteins were analyzed as ratio of phosphorylated:total protein. 
Duplicate western blots were performed for all experiments. 
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2.2.6 Isolation of RNA and cDNA Preparation 
 
A total of 450 μl tissue-homogenate-Tripur mix was diluted 1:10 with 1-Bromo-3-
chloropropane (Sigma-Aldrich, Zwijndrecht, the Netherlands) and shaken vigorously 
for 15 sec. After 10 min of incubation at room temperature, the samples were 
centrifuged at 12000 g, 4°C for 15 min. The upper layer containing RNA was pipetted 
into clean vials and precipitated by adding 250 μl isopropanol followed by another 10 
min incubation period. RNA was centrifuged at 12000 g, 4°C for 8 min resulting in 
RNA pellets and supernatants, which were removed to dissolve the RNA pellet in 1ml 
75% ethanol. The samples were centrifuged at 12000 g, 4°C for 5 min and after this 
ethanol was removed and RNA was dissolved in 20 μl of Milli-Q water. RNA was 
heated at 60°C for 5 min, followed by a short centrifugation, vortexing and another 
heating at 60°C for 5 min. RNA concentrations were determined by UV-vis 
absorbance spectroscopy (NanoDrop, Thermo Scientific, Rockford, IL, USA). RNA 
yields typically ranged from 0.16 to 1.08 μg/μl. cDNA was synthesized using the First 
Strand cDNA Synthesis Kit for qRT-PCR (Roche, Almere, the Netherlands). 
Amplicons were diluted to 1 μg RNA/10 μl Milli-Q. 1 μl oligo-(dT)-primer (50 μmol/l) 
was added before samples were heated for 10 min at 65°C. cDNA-mix was added 
containing 4 μl 5x RT-buffer, 2 μl dNTP-mix, 0.5 μl RNase inhibitor (40 U/μl), 0.5 μl 
RT (20 U/μl) and 2 μl Milli-Q water. The samples were heated at 55°C for 30 min and 
then heated at 85°C for 5 min. The cDNA samples were diluted with 60 μl Milli-Q 
water and stored at -80°C.  
 
2.2.7 Reverse Transcriptase Real Time PCR 
 
cDNA samples were diluted 1:5 in Milli-Q water before adding 5 μl Sybr Green I 
MasterMix (Roche, Almere, the Netherlands) and 0.5 μl of sense- and anti-sense-
primer for Cav-1, Cav-3, or glyceraldehyde-3-phosphatedehydrogenase (GAPDH) as 
reference gene (table 2) (all Invitrogen, Breda, the Netherlands). qRT-PCR was 
performed in the LightCycler480 (Roche, Almere, the Netherlands) with following 
conditions: Pre-incubation heating to 95°C for 10 min, followed by 45 cycles of 
amplification (95°C for 15 sec, 56°C for 10 sec, 72°C for 15 sec) and a melting curve 
analysis. Amplicons that showed amplification of nonspecific products were excluded 
from analyses. Subsequently for each amplicon its baseline was determined and 
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corrected using LinRegPCR software (AMC Heart Failure Research Center, 
Amsterdam, the Netherlands) according to Ruijter and colleagues (Ruijter et al., 
2009). Each amplicon was corrected for baseline fluorescence. Amplicons that did 
not reach Nq before cycle 45 were considered undetectable. The individual PCR 
efficiencies were calculated and amplicons with an efficiency <1.80 or >2.00 were 
excluded from further analyses. The mean efficiency of each target gene was used to 
calculate the starting concentration (N0) per amplicon. All samples were normalized 
to the N0 of the reference gene GAPDH. Differences in expression of the gene of 
interest in the experimental groups (I/R15 vs. I/R+He15) and Sham were calculated. 
 
2.2.8 Statistical Analyses 
 
Kruskal-Wallis tests with Dunn’s post hoc analyses were performed to determine 
differences of protein levels and mRNA-expression between the groups. GraphPad 
Prism 5 (GraphPad Software, La Jolla, CA, USA) was used to perform tests. 
Statistical significance was assumed if P<0.05. Variables are expressed as mean ± 
standard error of the mean (SEM). 
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3. Results 
 
3.1 Main Findings 
 
 Target Location I/R+He15 vs. I/R15 P-Value Figure 
mRNA Cav-1 AAR whole tissue ↑ P<0.05 8 A 
      
protein Cav-1 AAR Membrane ↑ P<0.01 9 A 
      
 Cav-3 AAR Membrane ↑ P<0.05 9 B 
  Serum ↑ P<0.05 11 B 
      
 Akt AAR Cytosol ↑ P<0.05 12 A 
  NAAR Cytosol ↑ P<0.05 13 A 
      
 Erk1 AAR Cytosol ↑ P<0.05 12 C 
  NAAR Cytosol ↓ P<0.001 13 C 
      
 Erk2 AAR Cytosol ↑ P<0.05 12 B 
  NAAR Cytosol ↓ P<0.001 13 B 
      
 Bcl-1 AAR Mitochondria ↑ P<0.05 14 A 
  NAAR Mitochondria ↑ P<0.05 14 B 
      
 
 
 
 
 
3.2 mRNA Expression Analyses of Caveolin-1 and Caveolin-3 
 
To measure mRNA expression of Cav-1 and Cav-3, qRT-PCR was performed with 
mRNA isolated from whole tissue (figure 7). In the ischemic tissue of the I/R15 group, 
both Cav-1 and Cav-3 showed significantly reduced mRNA expression [AAR: Cav-1, 
I/R15 (4.49±0.37) P<0.05 vs. Sham (6.81±0.91); figure 8 A; Cav-3, I/R15 (3.82±0.18) 
P<0.01 vs. Sham (5.06±0.29); figure 8 B]. The HePoc group presented increased 
Table 3 ▲ Main Findings. 
↑ significant increase   
↓ significant decrease  
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expression of Cav-1 in comparison to I/R, but no differences vs. Sham [AAR: Cav-1, 
I/R+He15 (5.65±0.25) P<0.05 vs. I/R15 (4.49±0.37); figure 8 A]. Cav-3 expression 
was also reduced after HePoc compared to Sham, but showed no differences vs I/R 
[AAR: Cav-3, I/R+He15 (3.54±0.21) P<0.001 vs. Sham (5.06±0.29); figure 8 B]. In the 
NAAR, Cav-1 and Cav-3 mRNA expression were lower after HePoc in comparison to 
Sham [NAAR: Cav-1, I/R+He15 (0.66±0.11) P<0.05 vs. Sham (1.58±0.34); figure 8 A; 
Cav-3, I/R+He15 (4.70±0.31) P<0.01 vs. Sham (6.70±0.38); figure 8 B]. No 
differences were found comparing mRNA expression of Cav-1 and Cav-3 between 
I/R15 and I/R+He15 in NAAR tissue. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.3 Protein Analyses of Caveolin-1 and Caveolin-3  
 
For protein analyses using western blot, the tissue was separated into cellular 
fractions as described in section 2.2.3 (figure 7). 
HePoc significantly increased accumulation of Cav-1 and Cav-3 in the membrane 
fraction of ischemic cardiac tissue, AAR, compared to Sham and I/R15 [AAR: Cav-1, 
I/R+He15 (45.53±8.38) P<0.01 vs. Sham (17.38±4.31); P<0.01 vs. I/R15 
figure 8 ▲ Quantification of mRNA Expression of Caveolin-1 and Caveolin-3 in Sham, 
I/R15 and I/R+He15 Treated Animals. mRNA expression of Cav-1 (A) and Cav-3 (B) was 
measured in AAR and NAAR tissue (red) using GAPDH as reference gene. mRNA levels are 
displayed as ratio of Cav-1 or Cav-3:GAPDH. Results show the mean ± SEM. A pound sign 
indicates differences vs. Sham (#=P<0.05, ##=P<0.01 ###=P<0.001), whereas the asterisk 
indicates differences vs. I/R15 (*=P<0.05). n=8 in each group. (Flick et al., 2016) 
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figure 9 ▲ Protein Levels of Caveolin-1 and Caveolin-3 in Membrane Fractions of 
Sham, I/R15 and I/R+He15 Treated Animals. Data are shown as ratios of Cav-1:tubulin 
(A) and Cav-3:tubulin (B) in AAR and NAAR membrane fractions (grey). Columns display 
the mean ± SEM. A pound sign indicates differences compared to Sham (#=P<0.05, 
##=P<0.01), whereas the asterisk indicates differences compared to I/R15 (*=P<0.05, 
**=P<0.01). Bands display a representative example of western blot analyses. Sham: n=6, 
I/R15 and I/R+He15: n=7. (Flick et al., 2016) 
(20.43±4.44); figure 9 A; Cav-3, I/R+He15 (12.62±2.35) P<0.05 vs. Sham 
(5.99±1.21); P<0.05 vs. I/R15 (6.52±1.13); figure 9 B]. In the NAAR tissue protein 
expression of caveolins in the membrane fraction did not show differences between 
groups (figure 9 A and B). In the cytosolic and mitochondrial fraction no differences of 
protein levels of Cav-1 and Cav-3 were detected in AAR or NAAR tissue (figure 10).  
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figure 10 ▲ Protein Levels of Caveolin-1 and Caveolin-3 in Cytosolic and 
Mitochondrial Fractions of Sham, I/R15 and I/R+He15 Treated Animals. Values are 
displayed as ratio of Cav-1 or Cav-3 and control protein actin (Act) in cytosol (A+B, blue) or 
prohibitin-1 (PHB1) for mitochondria (C+D, green). Columns display the mean ± SEM. 
Bands display a representative example of western blot analyses. n=7 in each group. (Flick 
et al., 2016) 
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Serum analyses did not present any differences of Cav-1 levels (figure 11 A), 
whereas serum from I/R+He15 group revealed increased amounts of Cav-3 [Serum: 
Cav-3, I/R+He15 (8.23±0.48) P<0.05 vs. I/R15 (6.79±0.41); figure 11 B].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
figure 11 ▲ Protein Levels of Caveolin-1 and Caveolin-3 in Serum of Sham, I/R15 and 
I/R+He15 Treated Animals. Data are shown as relative values of Cav-1 (A) and Cav-3 (B) in 
serum. Columns display the mean ± SEM. An asterisk indicates differences compared to I/R 
(*=P<0.05). Bands display a representative example of western blot analyses. Sham: n=4, 
I/R15 n=7, I/R+He15: n=7. (Flick et al., 2016) 
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3.4 Phosphorylation of RISK Pathway Associated Proteins 
 
Western blot analyses of RISK pathway associated proteins showed increased 
phosphorylation levels of Akt in the ischemic tissue [AAR: I/R+He15 (6.50±0.68) 
P<0.05 vs. Sham (4.51±0.49); P<0.05; vs. I/R15 (4.38±0.33); figure 12 A]. Increased 
amounts of pAkt were also detected in non-ischemic NAAR tissue after HePoc 
[NAAR: I/R+He15 (6.51±0.70) P<0.05 vs. I/R15 (4.35±0.30); figure 13 A]. Erk1 and 
Erk2 showed increased activation after I/R compared to Sham [AAR: Erk1, I/R15 
(12.37±1.54) P<0.01 vs. Sham (5.63±0.62); figure 12 B; Erk2, I/R (1.85±0.31) P<0.05 
vs. Sham (1.22±0.08); figure 12 C]. HePoc treated animals showed even higher 
phosphorylation levels of both Erk1 and Erk2 in the ischemic tissue compared with 
I/R15 [AAR: Erk1, I/R+He15 (14.57±0.93), P<0.05 vs. I/R15 (12.37±1.54); figure 12 
B; Erk2, I/R+He15 (2.68±0.18) P<0.05 vs. I/R15 (1.85±0.31); figure 12 C].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
figure 12 ▲ Phosphorylation Levels of RISK Pathway Associated Proteins in 
Ischemic AAR Cardiac Tissue of Sham, I/R15 and I/R+He15 Treated Animals. Data are 
shown as ratios of phosphorylated protein:total protein in the AAR cytosolic fraction (blue). 
Columns display the mean ± SEM. A pound sign indicates differences compared to Sham 
(#=P<0.05, ##=P<0.01, ###=P<0.001), whereas the asterisk indicates differences 
compared to I/R15 (*=P<0.05). Bands display a representative example of western blot 
analyses. n=7 in each group. (Flick et al., 2016) 
Results 
29 
NAAR tissue analyses revealed, that Erk1 and Erk2 phosphorylation was reduced vs. 
Sham in both I/R15 and I/R+He15 [NAAR: Erk1, I/R15 (2.23±0.30); I/R+He15 
(2.17±0.21) both P<0.001 vs. Sham (5.62±1.21); figure 13 B; Erk2, I/R15 
(4.51±0.32); I/R+He15 (5.03±0.42) both P<0.001 vs. Sham (12.25±1.08); figure 13 
C]. Phosphorylation levels of PI3K and PKCε showed no differences in any of the 
treatment groups (figure 12 D, 13 D, 12 E and 13 E). 
figure 13 ▲ Phosphorylation Levels of RISK Pathway Associated Proteins in Non-Ischemic 
NAAR Cardiac Tissue of Sham, I/R15 and I/R+He15 Treated Animals. Data are shown as 
ratios of phosphorylated protein:total protein in the NAAR cytosolic fraction (blue). Columns show 
the mean ± SEM. A pound sign indicates differences compared to Sham (###=P<0.001) whereas 
the asterisk indicates differences compared to I/R15 (*=P<0.05). Bands display a representative 
example of western blot analyses. n=7 in each group. (Flick et al., 2016) 
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3.5 Protein Analyses of Autophagy Associated Proteins 
 
Our analyses of sequestosome-1 showed no differences between Sham, I/R and 
HePoc in any of the investigated cell fractions in AAR or NAAR (not shown). Bcl-1 
levels in I/R15 group were significantly lower than Sham in both AAR and NAAR 
tissue [AAR: Bcl-1 I/R15 (1.99±0.14) P<0.05 vs. Sham (3.32±0.49); figure 14 A; 
NAAR: Bcl-1 I/R15 (2.70±0.12) P<0.05 vs. Sham (4.44±0.48); figure 14 B] However, 
Bcl-1 showed a significant increase after 15 min of HePoc in the mitochondrial 
fraction, similar results were found in both AAR and NAAR tissue [AAR: Bcl-1, 
I/R+He15 (2.62±0.17) P<0.05 vs. I/R15 (1.99±0.14); figure 14 A; NAAR: Bcl-1, 
I/R+He15 (3.77±0.17) P<0.05 vs. I/R15 (2.70±0.12); figure 14 B]. In the cytosolic and 
membrane fractions no significant differences were detected (not shown). 
 
 
 
 
 
 
3.6 Protein Analyses of Caveolin-1 and Caveolin-3 after 5 and 30 Min of                                                  
…...HePoc 
 
The results of western blot analyses of Cav-1 and Cav-3 in different cell 
compartments after 5 and 30 min of HePoc are not further described in the results 
section. No significant differences between the groups were found. The results are 
shown in the appendix (section 7.1 and 7.2). 
figure 14 ▲ Protein Levels of Bcl-1 in Mitochondrial Fractions of Sham, I/R15 and I/R+He15 
Treated Animals. Values are displayed as ratio of Bcl-1 and control protein Prohibitin-1 (PHB1). 
Figures show results in AAR (A) and NAAR (B) tissue. Columns display the mean ± SEM. A pound 
sign indicates differences compared to Sham (#=P<0.05), whereas the asterisk indicates differences 
compared to I/R15 (*=P<0.05). Bands display an example of western blot analyses. n=7 for each 
group. Based on (Oei et al., 2015b) 
 
 
B A 
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4. Discussion 
 
4.1 Helium Postconditioning and Cardioprotection 
 
The cardioprotective effects of helium have been replicated in different animals and 
models (Huhn et al., 2009b, Pagel et al., 2007, Pagel et al., 2008b). For this thesis 
we used tissue from a HePoc rat model, which was previously investigated for 
myocardial damage with best outcome after 15 min of HePoc (Oei et al., 2015b). The 
tissue was obtained immediately after performing I/R or HePoc. It is widely accepted 
that damaging effects of reperfusion injury occur within the first min. Therefore 
cardioprotective signaling induced by HePoc has to take effect with the onset of 
reperfusion to reduce damage (Kin et al., 2004).  
 
In line with the previous analyses of tissue profiles and infarct size (Oei et al., 2015b) 
our results indicate that duration of HePoc is of great importance. Too short, 5 min, or 
too long, 30 min, duration of HePoc showed no significant changes in protein 
expression in the different cellular fractions (section 7.1 and 7.2). Another HePoc rat 
model by Oei et al. showed similar results supporting the idea that duration of HePoc 
is of high importance (Oei et al., 2015a). Cardioprotection was also abolished in a rat 
model, where prolonged helium inhalation commenced with the onset of ischemia 
and continued for three hours of reperfusion (Hale et al., 2013). Other studies 
investigating liver protection and hepatic I/R came to a similar conclusion and 
showed no beneficial effect after elongated HePoc (Fukuda et al., 2007). In most 
studies no harmful side effects of helium ventilation were reported. Only a single 
study reports detrimental effects of helium conditioning in oxygen deprived human 
kidney cells after three hours of helium inhalation (Rizvi et al., 2010).  
 
However, further research will be necessary to determine the ideal duration of 
postconditioning, in order to transfer the findings of our study to human models (Oei 
et al., 2015a).  
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4.2 Helium Postconditioning and Caveolins 
 
Caveolins are important transmitters of pathways involved in cardioprotection and 
their repression in KO models reveals complete inhibition of advantageous effects in 
several settings (Yousuke T. Horikawa, 2014, Patel et al., 2007, Horikawa et al., 
2008). While the exact involvement of caveolins in cardioprotection is yet unknown, 
more recent studies revealed an important role in transmembrane signaling 
(Fridolfsson et al., 2014).  
 
In our setting we cannot confirm previous reports of caveolin reduction after I/R 
(Chaudhary et al., 2013), with no difference of Cav-1 and Cav-3 protein levels 
compared to Sham in any fraction of ischemic AAR tissue. However, our results 
show insignificant reduction of caveolin in the NAAR membrane and cytosolic fraction 
after both I/R and HePoc. As we understand, caveolins function mostly within 
membrane formations. Our analyses of the AAR membrane fraction revealed a 
significant increase of both, Cav-1 and Cav-3 after 15 min of HePoc. These results 
oppose recent results from Weber et al., who applied 30 min of helium ventilation in a 
mouse model. In their model Cav-1 analyses of whole cell protein levels presented 
significantly lower Cav-1 compared to the control group (Weber et al., 2013). 
Differences in used models, with longer helium ventilation and later tissue extraction, 
have to be taken in consideration, when comparing these results. Our findings of 
increased Cav-1 and Cav-3 in AAR membrane may indicate involvement of 
membrane-associated and therefore functioning, caveolins in HePoc-induced 
myocardial protection. Caveolins function as regulators for cellular processes. They 
are involved in metabolism and support compartmentalization of receptors and other 
proteins within the plasma membrane through their CSD (Ostrom, 2002, Patel et al., 
2008). Interaction with and localization to caveolins of cardioprotective RISK pathway 
kinases, e.g. Erk1/2, PI3K and Akt, have been shown in several studies (Shack et al., 
2003, Woodman et al., 2002, Smythe et al., 2006). A study by Ballard-Croft et al. 
even suggests that separate pathways can be activated specifically, when located to 
caveolar formations (Ballard-Croft et al., 2006). Underlining the importance of 
caveolins, the infusion of the CSD of Cav-1 into hearts undergoing I/R reduced 
cardiac damage (Young et al., 2001). However the exact role and purpose of 
caveolins within the membrane still need to be investigated. 
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In our study the analyses of mRNA expression showed a significant increase of Cav-
1 after HePoc compared to I/R in AAR tissue. The mRNA levels of Cav-1 in HePoc 
group reached values similar to Sham animals. However, due to our model design, 
no conclusion, whether levels were decreased after I/R and re-elevated by HePoc or 
remained the same during the whole protocol, can be made. Cav-3 expression on the 
other hand was significantly reduced in comparison to Sham in both, AAR and 
NAAR, with no difference to the I/R only group.  
 
Other studies with Cav-1 and Cav-3 KO models for I/R and conditioning protocols 
showed loss of cardioprotective effects in both designs (Patel et al., 2007, Tsutsumi 
et al., 2010a, Tsutsumi et al., 2010b). Overexpression of Cav-3 resulted in increased 
activation of respective pathways and even induced endogenous cardioprotection in 
a study conducted by Tsutsumi et al. (Tsutsumi et al., 2008). In addition, Cav-3 KO 
mice lack formation of caveolae and may present with cardiac hypertrophy and 
cardiomyopathy (Kikuchi et al., 2005). As mentioned earlier, the overexpression of 
Cav-3 lead to a significant increase of caveolae formation, improved cardiac function 
and innate cardioprotection against I/R (Tsutsumi et al., 2008, Horikawa et al., 2011). 
Overexpression of Cav-1 may result in inhibition of Erk1/2 signaling and vice versa, 
the activation of Erk1/2 has been shown to downregulate Cav-1 mRNA (Engelman et 
al., 1998). Our results show a different tendency with increased Erk1/2 activation and 
simultaneous mRNA upregulation of Cav-1 in AAR tissue. Interestingly Erk1/2 
phosphorylation was significantly lower in NAAR tissue of our model supporting the 
thesis of negative correlation. However, in NAAR tissue Cav-1 mRNA showed a 
tendency of reduced expression after I/R and HePoc. This was previously reported in 
an I/R rat model by Ballard-Croft et al. (Ballard-Croft et al., 2006). Our findings of 
reduced Cav-3 mRNA expression in AAR tissue differ from the findings in same 
study, where Cav-3 expression was not altered by I/R (Ballard-Croft et al., 2006).  
 
Our results indicate that HePoc not only induces changes of protein level, but also in 
mRNA expression. However, these changes are unlikely transferred into a protein 
response within the short time period for tissue extraction chosen in our current 
model. Nonetheless, they might indicate that I/R and HePoc induce long-term cellular 
responses. Even though the immediate effects of mRNA regulation are marginal, the 
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modulation of Cav-expression could benefit long term outcome and cardiac 
remodeling (Arslan et al., 2013). 
 
Besides the effects on mRNA level, we found not only increased Cav-1 and Cav-3 in 
the membrane, but also higher levels of Cav-3 in the serum of HePoc groups. 
Interestingly, the previously mentioned model, in which Cav-1 was depleted from the 
tissue, showed higher Cav-1 and Cav-3 levels in the serum as well (Weber et al., 
2013). 
 
Serum caveolin has been researched in different medical fields and discussed 
controversially. Increased serum levels have been found in various cancers including 
prostate (Sugie et al., 2013), colorectal (Erdemli et al., 2016) or lung cancer (Han et 
al., 2014). Data suggest that serum caveolin might be linked to pro-angiogenic and 
pro-survival mechanisms in tumors (Tahir et al., 2008). Protective characteristics in 
physiological states have been reported for prevention of right heart hypertrophy and 
subsequent pulmonary hypertension (Jasmin et al., 2006). In contrast lower Cav-1 
levels have been related to cerebral microbleeds. In the same study protective 
effects of circulating caveolins during acute cerebral bleeding are proposed 
supporting the idea of beneficial characteristics of caveolins in the serum (Zhang et 
al., 2016). Furthermore heart specific serum Cav-3 likely plays an important role in 
cardiac pathologies. Feiner et al. have reported significant decrease of Cav-3 in heart 
failure. Nonetheless the functioning of caveolins in the serum will need further 
investigation and the exact mechanism are yet unclear (Feiner et al., 2011). Together 
the current data points towards interactions between serum caveolins and specific 
tissue or organs.  
 
4.3 Helium Postconditioning and RISK Pathway Activation 
 
Recent studies have shown that mPTP signaling is transmitted through the CSD, an 
important binding site of caveolins (Fridolfsson et al., 2014). The CSD acts as a 
binding partner for many mediators and end-effectors involved in conditioning 
induced cardioprotection. One group of these known binding partners is RISK 
pathway associated kinases. These include the investigated kinases PI3K, Akt, PKCε 
and Erk1/2. PKCε and PI3K are known upstream mediators of Erk1/2 and Akt, which, 
when activated, cause inhibition of mPTP opening. Activation of these kinases has 
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been described for ischemic as well as pharmacological conditioning including 
anesthetic gases. Our findings of increased phosphorylation of Erk1/2 and Akt are in 
line with current opinion of these kinases as key players for cardioprotection. The 
analyses of Erk1/2 in the NAAR tissue, however, showed a significant decrease of 
Erk1/2 phosphorylation after I/R and HePoc. The implication of decreased Erk1/2 
activity after I/R and HePoc cannot be resolved completely, however Erk1/2 
decrease may lead to Cav-1 upregulation (Kavazis et al., 2008). Beneficial effects of 
Akt and Erk1/2 activation are not limited to cardiac tissue. Also activation of these 
kinases has been investigated as important factor in other organ-protection, e.g. 
neuroprotection, liver protection (Liu et al., 2016, Zhang et al., 2014). However, our 
results contradict previous (Huhn et al., 2009b), where 15 min of HePoc showed no 
effect on Erk1/2 and Akt phosphorylation in a similar model. In this study tissue was 
obtained 120 min after the onset of reperfusion. As phosphorylation may be 
processed quickly and cardioprotection occurs within the first min effects might not 
be visible after a longer time period.  
 
Our findings in the AAR tissue support the idea of Erk1/2 as a substantial component 
of HePoc induced cardioprotection. Pagel et al. discovered a strong dependency of 
cardioprotection on Erk1/2 as beneficial effects were abolished, when Erk1/2-
blockers were applied in a rabbit model. Interestingly the same model showed no 
infarct size reduction, when the upstream PI3K was blocked (Pagel et al., 2007). Our 
results reveal no increase in PI3K activation, but Akt, another downstream kinase of 
PI3K, showed significantly higher phosphorylation after HePoc compared to Sham 
and I/R only. Akt and Erk1/2 pathways have been identified as activators of eNOS, 
GSK-3β and inhibit Ca2+-induced opening of the mPTP. Our results indicate that the 
downstream kinases might be activated through other processes. Several studies 
have also detected higher phosphorylation of PKCε in xenon- as well as helium-
conditioning. Our model did not show alteration of PKCε phosphorylation in I/R or 
HePoc animals. Together these studies imply variation of signaling pathways 
between HePoc in different animal species as well as other conditioning procedures. 
Nevertheless it seems likely that similar end-effectors are involved. 
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4.4 Helium Postconditioning and Autophagy 
 
Previously published experiments from this animal model showed significant 
upregulation of genes associated with autophagy and reduction of apoptosis 
associated genes (Oei et al., 2015b). Our analyses, investigating effects of HePoc on 
proteins Bcl-1 and sequestosome-1, which are well established in autophagy 
(Klionsky et al., 2012), indicate increased activation of autophagy after HePoc. The 
HePoc group showed a significant increase of Bcl-1 in the mitochondrial fraction of 
both AAR and NAAR tissue. Together, this suggests a shift of Bcl-1 towards the 
membrane, which might indicate induction of autophagy as it is substantial for 
phagophore-formation during I/R (Matsui et al., 2007). Even though research 
indicates that I/R itself induces autophagy, different pharmacological conditioning 
agents have been shown to augment autophagy induction (Wei et al., 2016, Huang 
et al., 2010). Our results contradict other in vitro models, which reported significant 
increases and upregulation of Bcl-1 after I/R (Matsui et al., 2007). In vitro models 
using Bcl-1 heterozygous KO mice showed reduction of autophagosome formation. 
In contrary to previous studies, these animals developed smaller infarct sizes 
compared to wild-type animals (Matsui et al., 2007). Nevertheless, research of I/R in 
different organs strengthens the hypothesis that autophagy is protective during I/R 
(Zhang et al., 2015, Yang et al., 2015, Thapalia et al., 2016). Hence, the increased 
Bcl-1 in mitochondrial fraction after HePoc may play an important role for 
cardioprotective effects.  
 
The mRNA expression of another autophagy protein, sequestosome-1, was 
significantly upregulated in our model, as previously described (Oei et al., 2015b). 
However, our protein analyses of sequestosome-1 showed no significant difference 
of protein levels after HePoc compared to I/R only. Seqestosome-1 is involved in 
later processes of autophagy, consequently changes of sequestosome-1 may only 
be visible after a longer period of time.  
 
A recent in vitro study by Kassan et al. indicates a link between autophagy and 
caveolins. Cav-3 KO cells showed decreased expression of autophagy markers, 
whereas overexpression Cav-3 resulted in protection against I/R and preserved 
mitochondrial function (Kassan et al., 2016).  
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Erk1/2 is a cardioprotective effector kinase, which also has been discussed in 
autophagy (Zhu et al., 2007). A study investigating Parkinson’s disease provides 
evidence that Erk2 is an essential modulator of autophagy, including mitophagy 
(Dagda et al., 2008). Interestingly, in our model Erk1/2 showed higher activation in 
AAR tissue of HePoc groups. Erk1/2 may be involved in other signaling than 
described in section 4.3 and might be involved in pro-survival autophagy. However, 
our current setting gives no further insight on specific function or localization of 
Erk1/2, which might be an interesting aspect of further studies. Taken together our 
results may indicate increased autophagy initiation after HePoc. 
 
4.5 Caveolins and Mitochondria 
 
Within the cell, caveolins are not only important for cellular membrane associated 
processes, such as endocytosis or cellular signaling, but also have been identified to 
play key roles within the cell, e.g. mitochondrial functioning (Fridolfsson et al., 2012). 
Maintaining mitochondrial homeostasis during cellular stress in highly metabolic 
tissue, like myocardial muscle tissue, is crucial for cell survival. Fridolfsson et al. 
discovered that membrane-bound caveolin translocation from the plasma membrane 
to the mitochondria averts mitochondrial dysfunction and induces caveolin-dependent 
protective effects during cellular stress (Fridolfsson et al., 2012). Mitochondrial 
dysfunction may induce metabolic misbalance and eventually cause cell death. 
Several pathways leading to cell death emerge in the opening of the mPTP, which is 
especially eligible during cellular stress, like I/R (Hausenloy et al., 2003). As Pagel et 
al. showed in a rabbit model, mPTP opening is a key component of helium 
preconditioning induced cardioprotection as beneficial effects are eradicated, when 
atractyloside, a mPTP opener, is applied simultaneously (Pagel et al., 2007). Our 
protein analyses of the mitochondrial fraction showed no difference of Cav-1 or Cav-
3 levels between groups. Nonetheless increased levels of Cav-1 and Cav-3 in the 
membrane fraction as well as the serum caveolins may be a sign of increased 
caveolin trafficking, which could potentially be involved in maintenance of 
mitochondrial functioning. However, it is unlikely to see significant changes in protein 
amounts after such short period, making it more likely that the differences in the 
fractions are caused by translocation or other processes. 
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4.6 Limitations of the Study 
 
Due to the design of our study, with tissue extraction directly after the end of HePoc, 
we are able to investigate instant effects of HePoc. Some processes might only be 
activated and therefore measurable during reperfusion or at the end of HePoc 
intervention.  
 
In some cases, the heart might undergo short periods of ischemia during the 
performed surgical procedures. This might mimic IPC and therefore conflict with our 
HePoc protocol. However, the procedures were executed likewise in the different 
groups, including the Sham control group. Therefore, possible effects should be 
equal and out-cancel each other.  
 
Healthy young animals were employed in this study. Animal models with pathologies, 
e.g. diabetes or hypertension, which mimic the typical clinical patient, fail to show 
cardioprotection after HePoc (Huhn et al., 2009b). Most patients suffering from I/R 
present with several of these pathologies hindering the clinical translation.  
 
Using the described study design, a connection between HePoc and effects on 
caveolins, RISK pathway and autophagy can only be described as correlation. Even 
though a causality seems likely, our model cannot prove dependency of 
cardioprotective effects on the described pathways. Further experiments, e.g. 
blocking experiments, will be necessary to investigate causality between HePoc and 
the described targets. 
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4.7 Conclusion and Outlook 
 
The presented HePoc rat model enables us to explore the signaling pathways 
underlying the cardioprotective effects of helium.  
 
Our results support the hypothesis of a complex signaling network involved in HePoc 
induced cardioprotection. We conclude, that membrane-associated caveolins are 
important mediators of cardioprotective signaling and that RISK pathway kinases Akt 
and Erk1/2 as well as an activation of autophagy may also be essential for HePoc 
induced cardioprotection. Further experiments, including blocking experiments, are 
necessary to inhibit specific targets and to distinguish between correlation and 
causality of activated pathways. 
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5. Abstract 
 
Background: Short cycles of ventilation with anesthetic gases, such as isoflurane or 
xenon, prior to or after prolonged cardiac ischemia, called anesthetic pre- or 
postconditioning, are known to reduce cardiac damage. The underlying cellular 
mechanisms include the reperfusion injury salvage (RISK) pathway and recent 
studies also indicated recruitment of molecular signaling via caveolin (Cav) 
modulation. Postconditioning with the noble gas helium (HePoc) mimics 
cardioprotective effects. In the present study using a rat model, we investigated 
whether (1) HePoc alters protein or mRNA expression of Cav-1 and -3 and (2) 
activation of RISK pathway and (3) autophagy associated proteins. 
Materials and Methods: In a previous study our animal model was analyzed 
showing significantly lower histological damage and reduced infarct size after 15 min 
of HePoc (Oei et al., 2015b). Here, heliox ventilation (70% He, 30% O2) was applied 
after 25 min of ischemia and tissue from ischemic area at risk (AAR), non-ischemic 
not area at risk (NAAR), and serum was obtained. Cell fractions (cytosolic, 
mitochondrial, membrane) of Sham, I/R, I/R+He treated animals were separated and 
investigated for changes of Cav-1 and Cav-3 protein levels and mRNA expression 
(total tissue). Phosphorylation levels were measured to determine RISK pathway 
activation (Erk1/2, PI3K, PKCε and Akt). Protein levels of autophagy proteins Bcl-1 
and sequestosome-1 were also measured.  
Results: HePoc lead to an increase of Cav-1 mRNA expression compared to I/R 
only and additionally elevated levels of Cav-1 (P<0.01) and Cav-3 (P<0.05) in the 
membrane fraction of ischemic myocardium (AAR). RISK pathway kinase Akt was 
activated more in AAR and NAAR tissue of the HePoc group (both P<0.05). Erk1/2 
phosphorylation was higher in AAR (P<0.05) after HePoc. However in NAAR tissue 
of I/R and HePoc treated animals, pErk1/2 was lower compared to Sham (both 
P<0.001). PKCε and PI3K showed no significant changes in phosphorylation. 
Furthermore Bcl-1 was significantly elevated in the mitochondrial fraction after HePoc 
in AAR (P<0.05) as well as NAAR (P<0.05), while sequestosome-1 levels showed no 
difference between groups. 
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Conclusion: We propose that HePoc activates a network of signaling cascades, 
which in turn induce cardioprotection. Respective mediators may include caveolins, 
RISK pathway kinases and proteins involved in autophagy.  
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supplementary figure 1 ▲ Protein Levels of Caveolin-1 and Caveolin-3 in Sham, after 5 Min of 
I/R or I/R+HePoc in Cytosolic, Membrane and Mitochondrial Fractions of AAR and NAAR 
Tissue. Ratios are calculated as Cav-1:actin (cytosol A), Cav-1:PHB1 (mitochondria, C), Cav-1:tubulin 
(membrane, E) and Cav-3:actin (cytosol, B), Cav-3:PHB1 (mitochondria, D), Cav-3:tubulin 
(membrane, F). Columns display the mean ± SEM. AAR Membrane I/R+He5: n =6, other groups n=7 
(Flick et al., 2016) 
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7.1 Caveolin-1 and Caveolin-3 after 5 Min of Reperfusion or Helium 
…...Postconditioning 
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supplementary figure 2 ▲ Protein Levels of Caveolin-1 and Caveolin-3 in Sham, after 30 Min of 
I/R or I/R+HePoc in Cytosolic, Membrane and Mitochondrial Fractions of AAR and NAAR 
Tissue. Ratios are calculated as Cav-1:actin (cytosol A), Cav-1:PHB1 (mitochondria, C), Cav-1:tubulin 
(membrane, E) and Cav-3:actin (cytosol, B), Cav-3:PHB1 (mitochondria, D), Cav-3:tubulin 
(membrane, F). Columns display the mean ± SEM. NAAR Membrane I/R+He30: n =6, other groups 
n=7 (Flick et al., 2016) 
 
 
7.2 Caveolin-1 and Caveolin-3 after 30 Min of Reperfusion or Helium 
…...Postconditioning 
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7.3 Hemodynamics 
 
Group Baseline 24 Min of 
Ischemia 
5 Min of 
Reperfusion 
15 min of 
Reperfusion 
30 min of 
Reperfusion 
mean arterial pressure (mmHg) 
Sham 111 ± 13 113 ± 22 113 ± 21 98 ± 20 - 
I/R5 90 ± 33 95 ± 19 73 ± 20 - - 
I/R15 95 ± 24 93 ± 20 83 ± 21 62 ± 8 - 
I/R30 96 ± 29 91 ± 28 80 ± 24 79 ± 21 60 ± 15 
I/R+He5 102 ± 20 108 ± 23 78 ± 21 - - 
I/R+He15 102 ± 20 108 ± 17 96 ± 14 75 ± 11 - 
I/R+He30 97 ± 25 100 ± 24 95 ± 18 91 ± 23 69 ± 15 
mean heart rate (BPM) 
Sham 372 ± 20 373 ± 20 363 ± 24 352 ± 32 - 
I/R5 338 ± 29 354 ± 29 330 ± 18 - - 
I/R15 320 ± 60 340 ± 50 326 ± 46 306 ± 44 - 
I/R30 329 ± 62 359 ± 39 342 ± 38 346 ± 41 320 ± 39 
I/R+He5 360 ± 36 366 ± 16 344 ± 35 - - 
I/R+He15 338 ± 35 365 ± 36 350 ± 37 324 ± 34 - 
I/R+He30 343 ± 57 366 ± 36 347 ± 47 359 ± 40 328 ± 51 
  
supplementary table 1 ▲ Hemodynamics. Hemodynamics were measured after 15 min of baseline 
stabilization, 24 min of ischemia and after 5, 15 and 30 min of reperfusion. As analyzed by Oei et al., 
no statistical differences between the groups were found. Data are shown as mean ± standard 
deviation. (Oei et al., 2015b) 
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7.4  Moritz Flick, Martin Albrecht, Gezina T.M.L. Oei, Renske Steenstra, 
Raphaela P. Kerindongo, Coert J. Zuurbier, Hemal H. Patel, Markus W. 
Hollmann, Benedikt Preckel, Nina C. Weber; Helium postconditioning 
regulates expression of caveolin-1 and -3 and induces RISK pathway 
activation after ischemia/reperfusion in cardiac tissue of rats.               
Eur J Pharmacol. 2016 Nov 15; 791:718-725. 
doi:10.1016/j.ejphar.2016.10.012. 
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Hollmann, Benedikt Preckel, Nina C. Weber; Reduction of cardiac cell 
death after helium postconditioning in rats: transcriptional analysis of cell 
death and survival pathways. Mol Med. 2015 Jan 20; 20:516-26. 
doi:10.2119/molmed.2014.00057. 
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